ConductScience.org, home

Paper29285167

Effectiveness of C5a aptamers in a TNBS-induced colitis mouse model.

Li Z and 11 others. Exp Ther Med, 2017. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Effectiveness of C5a aptamers in a TNBS-induced colitis mouse model. Papers, record 29285167. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29285167

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness of C5a aptamers in a TNBS-induced colitis mouse model.
PubMed
Journal
Exp Ther Med
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.1
iCite
Revised in PubMed
2020-10-01
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li ZZhiping
2Wang XXiwen
3Chen MMan
4Wang YYuanyuan
5Sun RRui
6Qu HHan
7Sun YYu
8Gao WWeicun
9Li BBo
10Dong XXiaolin
11Zhang YYandong
12Xia ZZhiping

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19549758Therapeutic inhibition of the complement system.Pharmacol Rev1998https://conductscience.org/library/papers/9549758PubMed
225650554Role of the complement anaphylatoxin C5a-receptor pathway in atopic dermatitis in mice.Mol Med Rep2015https://conductscience.org/library/papers/25650554PubMed
312176911Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.Blood2002https://conductscience.org/library/papers/12176911PubMed
415771587Role of C5a in inflammatory responses.Annu Rev Immunol2005https://conductscience.org/library/papers/15771587PubMed
519902090Inhibition of thrombin activity with DNA-aptamers.Bull Exp Biol Med2009https://conductscience.org/library/papers/19902090PubMed
69973510In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha.J Immunol1999https://conductscience.org/library/papers/9973510PubMed
724831561The complement system in inflammatory bowel disease.Inflamm Bowel Dis2014https://conductscience.org/library/papers/24831561PubMed
87568051Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.Proc Natl Acad Sci U S A1995https://conductscience.org/library/papers/7568051PubMed
915660527Aptamers: an emerging class of therapeutics.Annu Rev Med2005https://conductscience.org/library/papers/15660527PubMed
1020592747Aptamers as therapeutics.Nat Rev Drug Discov2010https://conductscience.org/library/papers/20592747PubMed
119087411A second serine protease associated with mannan-binding lectin that activates complement.Nature1997https://conductscience.org/library/papers/9087411PubMed
1216154196A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.Ophthalmology2005https://conductscience.org/library/papers/16154196PubMed
1324499275Complement and its receptors: new insights into human disease.Annu Rev Immunol2014https://conductscience.org/library/papers/24499275PubMed
1410657289Adaptive recognition by nucleic acid aptamers.Science2000https://conductscience.org/library/papers/10657289PubMed
1510777714Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci.Am J Hum Genet2000https://conductscience.org/library/papers/10777714PubMed
1625277360Effectiveness of sildenafil and U-74389G in a rat model of colitis.J Surg Res2015https://conductscience.org/library/papers/25277360PubMed
1720044484The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction.J Biol Chem2010https://conductscience.org/library/papers/20044484PubMed
189200462Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding.J Immunol1997https://conductscience.org/library/papers/9200462PubMed
1914676676Role of C5a-C5aR interaction in sepsis.Shock2004https://conductscience.org/library/papers/14676676PubMed
2015476920Complement: a unique innate immune sensor for danger signals.Mol Immunol2004https://conductscience.org/library/papers/15476920PubMed

See all 34 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
29973488Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.Molecules2018https://conductscience.org/library/papers/29973488

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29285167

GET https://conductscience.org/api/papers/v1/29285167/references?page=2